For example, the NIAD researchers recently discovered that patients with a particularly aggressive form of the disease have a mutation in c-kit tyrosine kinase; such patients respond spectacularly well to the cancer ‘wonder drug’: imatinib mesylate (Gleevec). However, the most frequent mutations—those in c-kit D816—are relatively resistant to imatinib. “If you don’t find the 816 mutation you can tell parents that their child’s chances are pretty good,” says Metcalfe. The antibiotic geldanamycin (17-AAG), which inhibits Hsp90, is the latest recruit in the fight against mastocytosis as it destabilizes various kinases that are important in oncogenesis.
Sunday, July 01, 2007
Kinases? Oncogenesis? Tyrosine? What language is this?
Here it is:
Posted by BlueKat at 1:28 AM